[Management of febrile neutropenia in cancer patients]

Rev Med Liege. 2015 Apr;70(4):195-200.
[Article in French]

Abstract

The incidence of cancer is raising and the treatments are increasingly aggressive. Consequently, general practitioners, emergency departments, hematologists and oncologists are regularly facing a severe side-effect of cytotoxic therapy, febrile neutropenia (FN). FN is a serious complication of chemotherapy because it can be quickly fatal and causes a temporary or definitive cessation of treatment. In this article, we summarize the latest recommendations for the management of patients with FN under anti-cancer treatments.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy-Induced Febrile Neutropenia / diagnosis
  • Chemotherapy-Induced Febrile Neutropenia / therapy*
  • Drug Monitoring / methods
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Neoplasms / drug therapy*
  • Practice Guidelines as Topic
  • Risk Factors

Substances

  • Granulocyte Colony-Stimulating Factor